Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (September 2010)
39 slides from Pyc Therapeutics's investor presentation, Sep 3, 2010
Slide 1: Harnessing biodiversity for biologics discovery
Phylogica For personal use only Harnessing biodiversity for biologics discovery September 2010 Thursday, 2 September 2010
Slide 2: Introduction
Introduction Drug discovery and screening company based in Perth, Western Australia For personal use only Proprietary peptide libraries encoded from biodiverse bacterial genomes Accessing stable peptide structures from bacteria living in extreme environments Hybrid business model combines fee-for-se
Slide 3: Financial overview
Financial overview Listed on Australian stock Exchange (ASX:PYC) and Frankfurt (XETRA: PH7) For personal use only • 235.7M Ordinary shares, 22.7M Options • 1,340,000 convertible notes (which can convert to 26.8M shares) • Market capitalization of ~AU$15M Backed by Australia’s leading life science in
Slide 4: Experienced Executive Team
Experienced Executive Team Dr Douglas Wilson - Executive Chairman • Former Senior Vice-President, Medicine for Boehringer Ingelheim For personal use only • Overseen multiple drugs at all phases of development including bringing many drugs successfully to the market in the USA Dr Paul Watt – CEO • Co
Slide 5: Experienced Board
Experienced Board Mr Harry Karelis – Deputy Chairman • Established major Australian life sciences fund, BioTech Capital Ltd For personal use only • Board member of several private and public life sciences companies • Experience in financial analysis, fund management in Australia and overseas Mr Bruc
Slide 6: Lower Risk Business Model
Lower Risk Business Model Contract Drug Discovery for Pharma with In-House discovery For personal use only Thursday, 2 September 2010
Slide 7: Big Pharma are increasingly outsourcing drug discovery
For personal use only Big Pharma are increasingly outsourcing drug discovery Volume 9, March 2010, p183 Thursday, 2 September 2010
Slide 8: Discovery Partnerships: a marriage made in heaven
For personal use only Discovery Partnerships: a marriage made in heaven Small Biotech Big Pharma • Cash poor • Cash rich • Nimble • Slow Moving • Innovative • Conservative • Poor at clinical trials • Clinical trial experts • Poor at production/scale-up • Strong production/scale-up • Poor at marketin
Slide 9: Access to long-term revenue streams
For personal use only Access to long-term revenue streams Build long-term value through milestones and royalties • Secure increasing share of down-stream value through co-development, funded by surplus cash flow Thursday, 2 September 2010
Slide 10: Maximize near-term revenue
For personal use only Maximize near-term revenue Discovery Specialist Co-development Path Revenue Streams Near-term revenue from fee-for-service drug discovery and screening Screening peptide libraries against third-party drug targets No investment in each screening project required before initiatio
Slide 11: Successful companies focused on discovery-alliance model
Successful companies focused on discovery-alliance model Company Platform Market Value 2009 Revenues Listed For personal use only Morphosys Antibody Library Screening > $490M €81M DE Evolva Library Screening/Small Molecule > $320M CHF $19M SIX Evotec Genetic Library Screening/Small > $300M >€40M Fra
Slide 12: Evolva: a young specialist drug discovery company
Evolva: a young specialist drug discovery company Roche Discovery Deal (4/1/10) For personal use only Current Market Cap. $320 Million Thursday, 2 September 2010
Slide 13: M&A activity in biologics discovery points to value of libraries
M&A activity in biologics discovery points to value of libraries For personal use only Eight acquisitions of companies with biologics discovery libraries in less than 2 years • Average valuation at acquisition of $380M 62% of companies acquired at pre-clinical stage – a unique library is often the k
Slide 14: Phylomer libraries: the richest source of bioactive peptides
For personal use only Phylomer libraries: the richest source of bioactive peptides with activity against disease targets inside or outside cells Thursday, 2 September 2010
Slide 15: Addressing the challenge of peptide drug discovery
Addressing the challenge of peptide drug discovery Peptide market growing nearly twice as fast as small molecules For personal use only • 33 marketed peptides represent $4 billion market (excluding insulin) • Insulin market alone worth $14 billion • 178 peptides in clinical development • 400 peptide
Slide 16: Phylomer Peptides
Phylomer® Peptides Phylomers - new class of therapeutic peptides derived from natural For personal use only protein fragments (average size about 30 amino acids) Encoded from biodiverse bacterial genomes, many of which live in extreme environments like volcanic streams, geysers and deep sea volcanic
Slide 17: Harvesting the power of structural diversity for drug discovery
Harvesting the power of structural diversity for drug discovery For personal use only Phylomers libraries contain multiple classes of subdomain and supersecondary structures from diverse evolutionary protein lineages Thursday, 2 September 2010
Slide 18: Phylomers from multiple structural families with diversity of shapes
Phylomers from multiple structural families with diversity of shapes Bacteroides: (40L_0859) Bordetella: (40L_0716) Haloarcula: (40L_0735) For personal use only Homologous Crystal Structure S. enterica. E. coli. B. stearothermophilus (dTDP-D-glucose 4,6-dehydratase) (Ferric siderophore receptor) (Al
Slide 19: Phylomer versatility: can block intracellular and extracellular targets
Phylomer versatility: can block intracellular and extracellular targets Primary hits show in vitro and in vivo bioactivity against extracellular and intracellular target classes For personal use only • Intracellular screens: - In vitro: AP-1 pathway, MAL adaptor - In vivo: acute airways inflammation
Slide 20: Phylogica's Target-Based Deal Structure
Phylogica’s Target-Based Deal Structure For personal use only Discovery Pharma Partnerships (indicative terms) Value Per Drug Target (US$) Upfront license fee $500-$750K Contract Discovery (3-4 FTE’s/yr) $750K- $1M Cumulative Milestone Payments Up to $100M Royalties Single digit % Thursday, 2 Septem
Slide 21: Roche & MedImmune
Roche & MedImmune Roche For personal use only Signed December 2009 Discovery of new cell penetrating peptides Project completed and review of milestone achievements in progress $435,000 for option fee and a pre-negotiated 8 figure option exercise deal Full back license to Phylogica to cell penetrati
Slide 22: Strong intellectual property estate
For personal use only Strong intellectual property estate Patents cover methods of making and screening Phylomer libraries and composition-of-matter on peptides and the libraries themselves 16 patent families, 26 granted/ allowed patents and 27 patent applications covering the markets of US, Europe,
Slide 23: Phylogica's Focus on Drug Discovery (2009-)
Phylogica’s Focus on Drug Discovery (2009-) Core strength = a unique drug discovery engine and a rich source For personal use only of peptide drug leads Focusing on Drug Discovery model Phylogica Co-development path • Platform now fully supported and scaleable. • Business offering now gaining commer
Slide 24: Technical Validation of Phylomer libraries
For personal use only Technical Validation of Phylomer libraries Thursday, 2 September 2010
Slide 25: Phylomers bind multiple target classes
For personal use only Phylomers bind multiple target classes Thursday, 2 September 2010
Slide 26: Phylomer affinities before maturation (Primary hits)
Phylomer affinities before maturation (Primary hits) Primary phage screens identified many unique Phylomer hits against For personal use only CD40L with IC50’s under 500nM (Phage Competition ELISA) Peptides expressed as recombinant fusions with Maltose Binding Protein (MBP) and then affinities deter
Slide 27: Phylomer library advantages
For personal use only Phylomer library advantages Thursday, 2 September 2010
Slide 28: Phylomer library advantages
Phylomer library advantages High rates of functional peptide hits For personal use only • Biological activity, low-mid nM affinities • Fast discovery process Thursday, 2 September 2010
Slide 29: Phylomer library advantages
Phylomer library advantages High rates of functional peptide hits For personal use only • Biological activity, low-mid nM affinities • Fast discovery process Library versatility • Intracellular targets • Extracellular targets • Phenotypic screens Thursday, 2 September 2010
Slide 30: Phylomer library advantages
Phylomer library advantages High rates of functional peptide hits For personal use only • Biological activity, low-mid nM affinities • Fast discovery process Library versatility • Intracellular targets • Extracellular targets • Phenotypic screens Multiple sequence families in hits • Identify minimal
Slide 31: Phylomer peptide advantages
For personal use only Phylomer peptide advantages Thursday, 2 September 2010
Slide 32: Phylomer peptide advantages
Phylomer peptide advantages Amenable to chemical synthesis For personal use only • Scalable and controllable • Cost-effective • Customisation of drug properties Thursday, 2 September 2010
Slide 33: Phylomer peptide advantages
Phylomer peptide advantages Amenable to chemical synthesis For personal use only • Scalable and controllable • Cost-effective • Customisation of drug properties Alternative delivery potential • Intra-nasal, sub-lingual Thursday, 2 September 2010
Slide 34: Phylomer peptide advantages
Phylomer peptide advantages Amenable to chemical synthesis For personal use only • Scalable and controllable • Cost-effective • Customisation of drug properties Alternative delivery potential • Intra-nasal, sub-lingual Access to Intracellular targets (via protein transduction) Thursday, 2 September
Slide 35: Phylomer peptide advantages
Phylomer peptide advantages Amenable to chemical synthesis For personal use only • Scalable and controllable • Cost-effective • Customisation of drug properties Alternative delivery potential • Intra-nasal, sub-lingual Access to Intracellular targets (via protein transduction) Novel IP positions on
Slide 36: Well-positioned for commercial success
Well-positioned for commercial success Extensive evaluation studies validate high quality of Phylomer library hits For personal use only Multiple in vivo efficacy studies support therapeutic potential of Phylomer peptides Versatility of libraries endorsed by international research collaborations Dru
Slide 37: Phylogica's Discovery Partners
For personal use only Phylogica’s Discovery Partners Thursday, 2 September 2010
Slide 38: Summary
Summary Well positioned for commercial success For personal use only Unique drug discovery resource for pharmaceutical industry Technology is fully validated, scalable and optimized for commercialization Broad patent protection for entire class of drugs Initiated commercialization phase with two dea
Slide 39: Phylogica Ltd
Phylogica Ltd ASX: PYC For personal use only www.phylogica.com Thursday, 2 September 2010